ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2026
A Pilot Study of Cefepime and Meropenem Therapeutic Drug Monitoring in Pediatric Patients on Extracorporeal Therapy.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePatients on extracorporeal therapy receiving medications have the potential for large pharmacokinetic shifts. Data supporting dose adjustments for antibiotics in pediatric patients on extracorporeal membrane oxygenation (ECMO) or continuous renal replacement therapy (CRRT) are limited. Institutional data reveal that cefepime and meropenem troughs are often outside of goal ranges for patients on extracorporeal therapies. The objective of this research was to elucidate potential patterns between clinical characteristics, extracorporeal modalities, and total serum trough concentrations of cefepime and meropenem.
methodsThis retrospective chart review evaluated all patients during the study period with a cefepime or meropenem serum concentration obtained while on ECMO or CRRT. Clinical circumstances were reported, and descriptive statistics were performed on various subgroups to determine which subpopulations experienced more out-of-range drug trough concentrations.
resultsTwenty-one cefepime serum trough concentrations were reviewed for 11 patients, with the mean and median concentrations exceeding the pre-defined goal range. Fifty percent of serum cefepime concentrations from 6 patients on ECMO were supratherapeutic, whereas 92.9% of serum cefepime concentrations from 7 patients on CRRT were supratherapeutic. Seven serum meropenem concentrations were reviewed for 5 patients, and the mean, median, and IQR of the serum troughs were all within goal range, regardless of extracorporeal therapy used. All cefepime and meropenem serum trough concentrations that were collected after a pause in CRRT of at least 1 hour within the previous 24 hours exceeded the goal ranges. One possible neurotoxic event was identified in a patient receiving cefepime and CRRT.
conclusionsPharmacists and providers should ensure that pauses in CRRT are accounted for when dosing these antibiotics and should be aware that standard cefepime dosing for these patients often leads to elevated trough concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.